16:11 EDT Tandem Diabetes (TNDM) sees FY25 revenue $997M-$1.007B, consensus $999M
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- TNDM Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Tandem Diabetes price target lowered to $45 from $55 at RBC Capital
- Hold Rating for Tandem Diabetes Care Amid Competitive and Macroeconomic Challenges
- Tandem Diabetes initiated with a Neutral at Mizuho
- Tandem announces publication of results from trial of Control-IQ+ AID technology